Childhood atopic dermatitis: current developments, treatment approaches, and future expectations


Creative Commons License

Cetinkaya P. G., ŞAHİNER Ü. M.

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.49, sa.4, ss.963-984, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 49 Sayı: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.3906/sag-1810-105
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.963-984
  • Anahtar Kelimeler: Atopic dermatitis, childhood, pathogenesis, treatment, THYMIC STROMAL LYMPHOPOIETIN, TOPICAL CALCINEURIN INHIBITORS, SINGLE NUCLEOTIDE POLYMORPHISMS, PARTY DIAGNOSTIC-CRITERIA, HUMAN EPITHELIAL-CELLS, STAPHYLOCOCCUS-AUREUS, GENE POLYMORPHISMS, T-CELLS, TACROLIMUS OINTMENT, AMERICAN ACADEMY
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder of childhood. Underlying factors that contribute to AD are impaired epithelial barrier, alterations in the lipid composition of the skin, immunological imbalance including increased Th2/Th1 ratio, proinflammatory cytokines, decreased T regulatory cells, genetic mutations, and epigenetic alterations. Atopic dermatitis is a multifactorial disease with a particularly complicated pathophysiology. Discoveries to date may be considered the tip of the iceberg, and the increasing number of studies in this field indicate that there are many points to be elucidated in AD pathophysiology. In this review, we aimed to illustrate the current understanding of the underlying pathogenic mechanisms in AD, to evaluate available treatment options with a focus on recently discovered therapeutic agents, and to determine the personal, familial, and economic burdens of the disease, which are frequently neglected issues in AD. Currently available therapies only provide transient solutions and cannot fully cure the disease. However, advances in the understanding of the pathogenic mechanisms of the disease have led to the production of new treatment options, while ongoing drug trials also have had promising results.